Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia

Annals of Hematology

Volumn 86, Issue 10, 2007, Pages 741-747

  Colovic, Natasa ^a   Tosic, Natasa ^b   Aveic, Sanja ^b   Djuric, Marija ^b   Milic, Natasa ^c   Bumbasirevic, Vladimir ^c   Colovic, Milica ^a   Pavlovic, Sonja ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b Institute of Molecular Genetics and Genetic Engineering

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

AML; FLT3 mutations; Paired initial and relapsed samples; Prognostic significance

Indexed keywords

AMSACRINE; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PROTEIN TYROSINE KINASE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG TARGETING; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENE DUPLICATION; GENE MUTATION; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; STATISTICAL SIGNIFICANCE; YUGOSLAVIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; POINT MUTATION; RECURRENCE; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YUGOSLAVIA;

EID: 34548306949     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0325-3     Document Type: Article

References (43)

1. Abu-Duhier FM, Goodeve AC, Wilson GA et al (2000) FLT3 internal tandem duplications in adult acute myeloid leukemia define a high-risk group. Br J Haematol 111:190-195
2. Abu-Duhier FM, Goodeve AC, Wilson MA et al (2001) Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113:983-988
3. Baldwin BR, Tse KF, Small D (2001) Transgenic mice expressing a constitutively activated FLT3 receptor display a myeloproliferative disease phenotype. Blood 98:801
4. Bennet JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 103:620-629
5. Boissel N, Cayuela JM, Preudhomme C et al (2002) Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 16:1699-1704
6. Cloos J, Goemans BH, Hess CJ et al (2006) Stabillity and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20:1217-1220
7. Colovic M, Jurisic V, Pavlovic S et al (2006) FLT3/D835 mutation and inversion of chromosome 16 in leukemic transformation of myelofibrosis. Eur J Intern Med 17:434-435
8. Drexler HG (1996) Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 10:1584-1591
9. Gabbianelli M, Pelosi E, Montesoro E et al (1995) Multilevel effects of flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 86:1661-1670
10. Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532-1542
11. Grimwade D, Walker K, Oliver F et al (1998) The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1.612 patients entered into MRC AML trial. The Medical Reserch Council Adult and Children's Leukemia Working Parties. Blood 92:2322-2333
12. Grundler R, Miething C, Thiede C et al (2005) FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantational model. Blood 150:4792-4800
13. Haferlach T, Schoch C, Schnittger S et al (2002) Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): A study of 124 patients. Br J Haematol 118:426-431
14. Hayakawa F, Towatari M, Kiyoi H et al (2000) Tandem duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624-631
15. Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80:213-223
16. Jiang J, Paez JG, Lee JC et al (2004) Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 104:1855-1858
17. Kiyoi H, Naoe T, Yokota S et al (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocitic leukemia. Leukemia 11:1447-1452
18. Kottaridis PD, Gale RE, Frew ME et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759
19. Kottaridis PD, Gale RE, Langabeer SE et al (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patient with acute myloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100:2393-2398
20. Kottaridis PD, Gale RE, Linch DC (2003) Prognostic imlications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma 44:905-913
21. Matthews W, Jordan CT, Wiegand GW et al (1991) A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65:1143-1152
22. Mitelman F (ed) (1995) An international system for human cytogenetic nomenclature. Karger, Basel, Switzerland
23. Nakao M, Yokota S, Iwai T et al (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911-1918
24. Nakano Y, Kiyoi H, Miyawaki S et al (1999) Molecular evolution of acute myeloid leukemia in relapse: Unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 104:659-664
25. Piccaluga PP, Biancchini M, Martinelli G (2003) Novel FLT3 point mutation in acute myeloid leukaemia. Lancet Oncol 4:604
26. Rappold I, Ziegler BL, Kohler I et al (1997) Functional and phenotypic characterisation of cord blood and bone marrow subsets expressing FLT3 (CD 135) receptor tyrosine kinase. Blood 90:111-125
27. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE (2000) Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14:675-683
28. Rosnet O, Marchetto S, de Lapeyriere O, Birnbaum D (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 6:1641-1650
29. Rosnet O, Buhring HJ, Marchetto S et al (1996) Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10:238-248
30. Sanz MA, Martin G, Vellenga E et al (2005) Risk-adapted treatment of acute promyelocytic leukemia: Updated results of the Spanish PETHEMA LPA99 Trial using ATRA and anthracycline monochemotherapy. J Clin Oncol 23:6515
31. Schittenhelm MM, Yee KWH, Tyner JW et al (2006) FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 20:2008-2014
32. Schnittger S, Schoch C, Dugas M et al (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia (AML): correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study, and usefulness as a marker for detection of minimal residual disease. Blood 100:59-66
33. Scholl S, Loncarevic IF, Krause C et al (2005) Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. Leuk Res 29:849-853
34. Shih LY, Huang CF, Wu JH et al (2004) Heterogenous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: A comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin Cancer Res 10:1326-1332
35. Small D (2006) FLT3 mutations: Biology and treatment. Hematology 2006:178-184
36. Spiekermann K, Bagrintseva K, Schoch C et al (2002) A new and recurrent activating lenght mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 100:3423-3425
37. Stirewalt DL, Mechinchi S, Kussick SJ et al (2004) Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol 124:481-484
38. Thiede C, Steudel C, Mohr B et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335
39. Ulrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212
40. Wheatley K, Burnett AK, Goldstone AH et al (1999) A simple robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derived from MRC AML 10 trial. United Kingdom Medical Resourch Council's Working Parties. Br J Haematol 107:69-79
41. Yanada M, Matsuo K, Suzuki T et al (2005) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia 19:1345-1349
42. Yamamoto Y, Kiyoi H, Nakano Y et al (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematological malignancies. Blood 97:2434-2439
43. Zwaan CM, Meshinchi S, Radich JP et al (2003) FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: Prognostic significance and relation to celllular drug resistance. Blood 102:2387-2394